This two day, interactive seminar which provides a conduit to enhance your understanding of the Continued Process Verification, will be reviewed in detail: where does it begin; what is included; and, when does it end.
These questions will be addressed within Stage 2 as presented here and include utilization of Process Validation and Phase 1, 2 and 3, where their Guidances blend and where they remain distinct. In particular, Stage 3.
Agenda
Day 01 (8:30 AM - 5:00 PM)
08.30 AM - 09.00 AM: Registration
09.00 AM: Session Start
Introduction, Goals and Objectives, Definitions. Process Validation - Its Importance within the Drug Industry
Interaction of the Three Stages with Process Validation
Validation Approaches, cGMPs in Clinical Supply Manufacture, Special Manufacturing Situations within Phase 1
The Requirements of Phase 1 Investigational Drug Requirements
Regulatory Strategies for Phase 2 and 3 and their Incorporation within Stages 1 and 2
Day 02 (8:30 AM - 4:30 PM)
General Considerations for Process Validation - Stage 2 Process Qualifications
Special Considerations for Process Validation - Stage 2
General Considerations for Process Validation - Stage 3 Continued Process Verification
A Review of EU Annex 15 and its Comparison to FDA's Process Validation Guidance
Concurrent Release of Process Performance Qualification (PPQ) Batches
Analytical Methodology and Process Validation; Warning Letter examples
Proov, the creator of a suite of at-home fertility-related hormone tests, has announced today that an equity share of the company has been purchased by GRAMMY award-winning singer-songwriter, actor and author Ashanti and her fiancé, GRAMMY winning,...
The National Council on Aging (NCOA), the national voice for every person's right to age well, is hosting its 2024 Age+Action Conference on May 6-8, 2024, in Arlington, VA....
Prevent Blindness, the nation's leading nonprofit eye health and safety organization, has designated May as "Inherited Retinal Disease (IRD) Genetic Testing Awareness Month," expanding its previous IRD and Genetic Testing Awareness Week initiative....
Children's Minnesota and Minnesota Epilepsy Group are pleased to announce the re-accreditation of their epilepsy monitoring unit as a Level 4 Epilepsy Center. This accreditation is the highest of its kind by the National Association of Epilepsy...
Co-Diagnostics, Inc. (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company will be hosting a booth and delivering a...
Alaffia Health, the leader in generative AI for health plan claim operations, today announced $10M in Series A funding, bringing its total amount of capital raised to $17.6M. The round was led by FirstMark Capital, with participation from GingerBread...